Still at #SITC2019? We’re presenting two posters today, one of which shares updates on our SRF617 program, a potent enzymatic inhibitor of CD39 that engages both the innate and adaptive immune system. See our poster: https://t.co/fu8JlIGjCb #ImmunoOncology